01 Shift Toward Longer-Acting Contraceptive Options The intrauterine contraceptive devices market analysis demands for reliable contraception with minimal user involvement is shifting preferences toward long-acting reversible methods, supporting greater adoption of IUDs; WHO states that copper IUDs can provide protection for 10–12 years, while hormonal IUDs can last 3–8 years, depending on the product.
02 Greater Emphasis on Person-Centered Contraceptive Choice WHO’s 2025 Medical Eligibility Criteria includes more than 2,000 recommendations across 25 contraceptive methods based on medical and physiological characteristics. For instance, the updated WHO guidance emphasizes informed choice and access to the contraceptive method that best suits individual needs, supporting more tailored use of intrauterine contraceptive devices.
01 Growth in Public-Sector Contraceptive Procurement and Expansion of Family Planning Services in Underserved Regions Drive Market Government purchasing of IUDs creates stable institutional demand and gives manufacturers greater visibility over recurring order volumes.Public procurement programs also improve product availability through distribution across hospitals, primary health centers, and other public facilities.India’s public health system, for example, supplies IUCD 380A and Cu IUCD 375 through multiple levels of facilities, supporting consistent market demand.Such procurement activity strengthens the supply chain and supports broader adoption of IUD products.Family planning service coverage in underserved areas brings IUD products to populations with limited access to contraceptive care. Healthcare facilities, trained providers, and outreach programs increase the number of locations where IUD insertion services are available. India’s Mission Parivar Vikas expanded family planning services across high-fertility districts, while public facilities provide IUD services through trained healthcare workers. Wider service coverage increases the potential user base and supports sustained demand for IUDs.
01 Misinformation and Social Stigma and Infrastructure and Follow-Up Requirements Limit Market Expansion Misinformation and social stigma around IUD safety, fertility, and eligibility can discourage potential users from considering the method. Limited access to accurate counseling allows myths and social opposition to influence contraceptive decisions, reducing demand and acceptance. Provider-led education and reliable contraceptive information remain important for addressing these concerns and improving confidence in IUD use. Lower acceptance limits the conversion of unmet contraceptive needs into IUD adoption and slows market growth.IUD service infrastructure and follow-up capacity influence the availability and continuity of services, particularly in underserved areas. Gaps in referral networks and post-insertion care can further discourage healthcare providers from expanding IUD services in remote locations. Service limitations reduce effective market access and constrain demand growth across regions with weaker healthcare systems.
01 Integration of Digital Contraceptive Counseling and Development of Next-Generation IUD Designs Generate Expansion Opportunities Twentyeight Health, for example, offers online contraception consultations and has partnered with Clue to connect users with provider-led birth control counseling. Such platforms can generate revenue through consultation services, memberships, partnerships, and broader contraceptive-care offerings. Healthcare providers and IUD manufacturers can also use these channels to improve product education and reach potential users earlier in the decision-making process.Medical device manufacturers and reproductive-health companies can benefit from demand for IUDs with improved insertion, comfort, usability, and clinical performance. New device designs can create differentiated product portfolios and support premium pricing while expanding adoption among users concerned about existing IUD experiences. The opportunity provides manufacturers with additional revenue through new product launches, upgraded device platforms, and stronger healthcare-provider demand.
01 Supply Chain & Raw Material Volatility and Dependence on Procurement & Distribution Networks Reduces Growth Potential Material availability and supply chain reliability create operational challenges for IUD manufacturers that depend on specialized components and medical-grade materials. Production delays or higher input costs can disrupt inventory planning, increase manufacturing expenses, and reduce supply consistency across markets. For example, copper price volatility in 2026 has raised concerns about higher manufacturing costs for copper-dependent products, creating margin pressure for device manufacturers.Procurement concentration and distribution network dependence can make revenue growth difficult for manufacturers that rely heavily on government tenders, donors, or centralized purchasing systems. Changes in funding, purchasing volumes, or distribution priorities can create uneven demand and leave suppliers with excess inventory or delayed orders. The 2025 reduction in U.S. foreign-aid funding left contraceptive supplies, including IUDs, stranded in warehouses and disrupted established distribution channels.
May 2026 Bayer expanded its intrauterine contraceptive device portfolio with continued investments in hormonal IUD technologies and patient access initiatives to support long-acting reversible contraception adoption.
March 2026 CooperSurgical strengthened its Paragard® copper intrauterine device portfolio by expanding availability and improving healthcare provider support programs for non-hormonal contraception.
October 2025 Organon expanded its women's health portfolio by enhancing access to long-acting contraceptive solutions, including intrauterine systems, across emerging and developed markets.
June 2025 AbbVie strengthened its women's health pipeline through investments in reproductive health technologies and partnerships supporting innovative contraceptive solutions.